Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03644953 · ClinicalTrials.gov registry record · Phase 2
Hydroxyurea and Transfusion
A Phase 2 study, sponsored by Children's National Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03644953: Completed Phase 2 study, sponsored by Children's National Research Institute.
NCT03644953 is a Phase 2 study that has completed, run by Children's National Research Institute. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03644953, a Phase 2 study, has completed, sponsored by Children's National Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will prospectively investigate the feasibility, safety, and transfusion requirements of adding hydroxyurea to simple chronic transfusions for patients with sickle cell anemia already on chronic transfusions.
Primary Outcome
number of participants who enroll on the study / total number of eligible subjects
Interventions
- DRUG Hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 2 |
What the finished NCT03644953 record still lists
NCT03644953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Hydroxyurea is the first listed.
NCT03644953 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03644953 about?
NCT03644953 is a clinical study titled "Hydroxyurea and Transfusion". This study will prospectively investigate the feasibility, safety, and transfusion requirements of adding hydroxyurea to simple chronic transfusions for patients with sickle cell anemia already on chronic transfusions.
What is the current status of trial NCT03644953?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2018-10-30. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT03644953?
The interventions under investigation include: Hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT03644953?
This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03644953's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy